Farah H. Abdalbari , Benjamin N. Forgie , Edith Zorychta , Alicia A. Goyeneche , Abu Shadat M. Noman , Carlos M. Telleria
{"title":"The gold complex auranofin sensitizes platinum resistant epithelial ovarian cancer cells to cisplatin","authors":"Farah H. Abdalbari , Benjamin N. Forgie , Edith Zorychta , Alicia A. Goyeneche , Abu Shadat M. Noman , Carlos M. Telleria","doi":"10.1016/j.bbrep.2025.101996","DOIUrl":null,"url":null,"abstract":"<div><div>Although numerous drugs have been tested to treat ovarian cancer (OC), survival rates remain low as there has been no major improvement from platinum (Pt)–based therapy and there is a high rate of Pt resistance in these tumors. Following several rounds of chemotherapy, OC cells develop Pt-resistance by increasing DNA repair and antioxidant defense mechanisms. This study aimed to design a treatment to combat recurrent stages of OC by repurposing the anti-rheumatic gold complex auranofin (AF). We demonstrate that AF enhances the efficacy of cisplatin (CDDP) in Pt-resistant epithelial OC (EOC) cells. The drug combination enhanced mitochondrial-dependent apoptosis, PARP cleavage, DNA damage, and ROS overproduction. These results suggest the potential to combine AF with CDDP as a strategy to improve CDDP sensitivity in recurrent EOCs.</div></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":"42 ","pages":"Article 101996"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405580825000834","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Although numerous drugs have been tested to treat ovarian cancer (OC), survival rates remain low as there has been no major improvement from platinum (Pt)–based therapy and there is a high rate of Pt resistance in these tumors. Following several rounds of chemotherapy, OC cells develop Pt-resistance by increasing DNA repair and antioxidant defense mechanisms. This study aimed to design a treatment to combat recurrent stages of OC by repurposing the anti-rheumatic gold complex auranofin (AF). We demonstrate that AF enhances the efficacy of cisplatin (CDDP) in Pt-resistant epithelial OC (EOC) cells. The drug combination enhanced mitochondrial-dependent apoptosis, PARP cleavage, DNA damage, and ROS overproduction. These results suggest the potential to combine AF with CDDP as a strategy to improve CDDP sensitivity in recurrent EOCs.
期刊介绍：
Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
